10.03.2018 Views

(medicalmingle.com) Top 5 Antibody Humanization Service Providers in the Antibody Market

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

<strong>Top</strong> 5 <strong>Antibody</strong> <strong>Humanization</strong> <strong>Service</strong> <strong>Providers</strong> <strong>in</strong> <strong>the</strong> <strong>Antibody</strong> <strong>Market</strong><br />

<strong>Top</strong> 1 GenScript<br />

Founded <strong>in</strong> 2002 <strong>in</strong> New Jersey, United States, GenScript serves as a partner for researchers <strong>in</strong><br />

basic life sciences, translational and biomedical fields as well as early-stage drug development.<br />

As a one-stop supplier for <strong>the</strong>rapeutic antibody discovery and development, GenScript is proud to<br />

offer <strong>in</strong>tegrated antibody humanization and aff<strong>in</strong>ity maturation service. Comb<strong>in</strong><strong>in</strong>g <strong>in</strong> silico<br />

CDR-graft<strong>in</strong>g, structure-based back mutation, and, supported by our patented FASEBA(Fast<br />

Screen<strong>in</strong>g for Expression, Biophysical-properties and Aff<strong>in</strong>ity) screen<strong>in</strong>g, Biacore Surface<br />

Plasmon Resonance platform and functional assay platform, <strong>the</strong> antibody humanization service is<br />

offered at GenScript to generate humanized antibody ma<strong>in</strong>ta<strong>in</strong><strong>in</strong>g <strong>the</strong> aff<strong>in</strong>ity and specificity of<br />

parental antibody and optimized activity, productivity and <strong>the</strong>rmostability. Seamlessly <strong>in</strong>tegrated<br />

with humanization, <strong>the</strong> aff<strong>in</strong>ity maturation service will cont<strong>in</strong>uously improve <strong>the</strong> aff<strong>in</strong>ity by 10 to<br />

50 folds.<br />

<strong>Top</strong> 2 S<strong>in</strong>o Biological<br />

Founded by MIT professor, Dr. Daniel I.C. Wang, and his former student, Dr. Liangzhi Xie, <strong>in</strong><br />

2007, S<strong>in</strong>o Biological Inc. is a develop<strong>in</strong>g biological reagents manufacturer located <strong>in</strong> Beij<strong>in</strong>g,<br />

offer<strong>in</strong>g a <strong>com</strong>prehensive set of premium quality reagents, all of which are produced <strong>in</strong>-house and<br />

cover a broad range of life science research and drug development.<br />

S<strong>in</strong>o Biological's antibody humanization experience covers not only mouse antibody but also<br />

rabbit monoclonal antibody. Our record speed for antibody humanization was 2 weeks, <strong>in</strong>clud<strong>in</strong>g<br />

antibody molecule structure modification, high-throughput antibody production by transient<br />

transfection, antibody characterization and bioactivity measurement.<br />

<strong>Top</strong> 3 Creative Biolabs<br />

S<strong>in</strong>ce its establishment <strong>in</strong> 2005 <strong>in</strong> New York, Creative Biolabs is specialized <strong>in</strong> provid<strong>in</strong>g custom<br />

biotechnology and pharmaceutical services that cover <strong>the</strong> full scope of biotechnology needs of<br />

early antibody development and drug discovery. It has extensive experience to offer <strong>the</strong> antibody<br />

humanization service for <strong>the</strong>rapeutic and diagnostic development. It has successfully performed<br />

15 mouse/rat humanization projects dur<strong>in</strong>g <strong>the</strong> past decade with at least one humanized antibody<br />

entered <strong>the</strong> cl<strong>in</strong>ical trials. It also provides humanization service to antibodies derived from o<strong>the</strong>r<br />

species, such as non-human primate (NHP), rabbit, dog, chicken, llama and etc.<br />

As a means of circumvent<strong>in</strong>g <strong>com</strong>mon problems, Creative Biolabs has developed three antibody<br />

humanization strategies that can preserve <strong>the</strong> specificity and aff<strong>in</strong>ity of <strong>the</strong> antibody toward <strong>the</strong><br />

antigen whereas significantly or <strong>com</strong>pletely elim<strong>in</strong>ate <strong>the</strong> immunogenicity of <strong>the</strong> antibody <strong>in</strong><br />

humans. The first approach is CDR graft<strong>in</strong>g and <strong>the</strong> second is cha<strong>in</strong> shuffl<strong>in</strong>g. These two methods<br />

are all based on phage display of humanized scFv variants and selection of high-aff<strong>in</strong>ity


humanized b<strong>in</strong>ders through bio-pann<strong>in</strong>g. The third method, humanized IgG library screen<strong>in</strong>g, is<br />

somehow unique. It will make a library of humanized whole IgG to be displayed on <strong>the</strong> surface of<br />

mammalian cells and <strong>the</strong>n high aff<strong>in</strong>ity b<strong>in</strong>ders will be sorted by FACS.<br />

<strong>Top</strong> 4 Fusion Antibodies<br />

Fusion Antibodies is a Contract Research Organisation (CRO) established <strong>in</strong> 2001 and located<br />

about 6 miles outside Belfast city centre <strong>in</strong> Nor<strong>the</strong>rn Ireland, UK. Its mission is to enable<br />

biopharmaceutical and diagnostic <strong>com</strong>panies to develop <strong>in</strong>novative products <strong>in</strong> a timely and<br />

cost-effective manner for <strong>the</strong> benefit of <strong>the</strong> global healthcare <strong>in</strong>dustry.<br />

Built on decades of <strong>com</strong>b<strong>in</strong>ed experience <strong>in</strong> <strong>the</strong> antibody development <strong>in</strong>dustry, its CDRx TM<br />

platform enables a robust, reliable and accurate modernized version of <strong>the</strong> CDR graft<strong>in</strong>g technique.<br />

It identifies and <strong>com</strong>b<strong>in</strong>es <strong>the</strong> essential sequences from antibody variable doma<strong>in</strong>s <strong>in</strong>to human<br />

donor sequences to create a panel of full length humanized antibodies for expression. The Fusion<br />

Antibodies humanization platform produces antibodies which are <strong>com</strong>pliant with <strong>the</strong> WHO/INN<br />

def<strong>in</strong>itions of a humanized antibody to receive <strong>the</strong> -zu- species orig<strong>in</strong> substem.<br />

<strong>Top</strong> 5 Absolute <strong>Antibody</strong><br />

Absolute <strong>Antibody</strong> was founded <strong>in</strong> Oxford, UK, <strong>in</strong> August 2012, with <strong>the</strong> vision that all antibody<br />

users should be able to use re<strong>com</strong>b<strong>in</strong>ant antibodies, which are absolutely def<strong>in</strong>ed by <strong>the</strong>ir am<strong>in</strong>o<br />

acid sequence. Ra<strong>the</strong>r than creat<strong>in</strong>g entirely new antibodies (or antibody-like molecules), it is<br />

build<strong>in</strong>g a catalog by tak<strong>in</strong>g exist<strong>in</strong>g antibodies (often from hybridomas) <strong>the</strong>n manufactur<strong>in</strong>g <strong>the</strong>m<br />

<strong>in</strong> a superior way and improv<strong>in</strong>g <strong>the</strong>ir usefulness by eng<strong>in</strong>eer<strong>in</strong>g.<br />

Absolute <strong>Antibody</strong> delivers a panel of humanized variants from your clone, and guarantee to<br />

produce a variant with <strong>com</strong>parable activity to <strong>the</strong> parent. Its process also identifies variants with<br />

preferential manufactur<strong>in</strong>g criteria (e.g. high expression, low aggregation).<br />

http://www.<strong>medicalm<strong>in</strong>gle</strong>.<strong>com</strong>/biotech/blog/?message=WW91ciBibG9nIHBvc3QgaGFzIGJlZW<br />

4gc3VibWl0dGVkIGFuZCB3aWxsIGJlIHBvc3RlZCBhZnRlciBhIG1vZGVyYXRvciBhcHByb3Z<br />

lcyBpdC4.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!